CoChat

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants

Open access
Timmers, Maarten, Barão, Soraia, Van Broeck, Bianca, Tesseur, Ina, Slemmon, John, De Waepenaert, Katja, Bogert, Jennifer, Shaw, Leslie M., Engelborghs, Sebastiaan, Moechars, Dieder, Mercken, Marc, Van Nueten, Luc, Tritsmans, Luc, de Strooper, Bart, Streffer, Johannes Rolf · 2017 · Journal of Alzheimer’s Disease
Cited by 32

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimer’s disease (AD) pathology. Increased BACE1 levels and activity have been reported in the brain of patients with sporadic AD. Therefore, changes of BACE1 levels in the cerebrospinal fluid (CSF) have also been investigated as a possible biomarker of the disease. We analyzed BACE1 levels in CSF of elderly healthy participants before and after chronic treatment with a BACE inhibitor (BACEi) and evaluated the correlation between BACE1 levels and downstream AD markers. Overall, BACE1 CSF levels showed strong correlations to all downstream AD markers investigated. This is the first reported finding that shows BACE1 levels in CSF were well correlated to its end product Aβ 1 - 42 . As previously described, BACE1 levels were strongly correlated to total-tau and phosphorylated tau levels in CSF. Generally, chronic BACE inhibition did not influence BACE1 CSF protein levels. Follow-up studies including early-stage AD pathophysiology and prodromal AD patients will help to understand the importance of measuring BACE1 routinely in daily clinical practice and AD clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-160829

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 32

Metadata

Authors
Timmers, M., Barão, S., Van Broeck, B., Tesseur, I., Slemmon, J., De Waepenaert, K., Bogert, J., Shaw, L. M., Engelborghs, S., Moechars, D., Mercken, M., Van Nueten, L., Tritsmans, L., de Strooper, B., & Streffer, J. R.
Venue
Journal of Alzheimer’s Disease
Published
2017-02
Volume
56
Issue
4
Pages
1437-1449
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2583227116
Cited by
32
References
12
FWCI
2.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants. https://app.cochat.ai/papers/10.3233/jad-160829
The paper
Timmers, M., Barão, S., Van Broeck, B., Tesseur, I., Slemmon, J., De Waepenaert, K., Bogert, J., Shaw, L. M., Engelborghs, S., Moechars, D., Mercken, M., Van Nueten, L., Tritsmans, L., de Strooper, B., & Streffer, J. R. (2017). BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-160829

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.